In mid November 2008, in common with many other firms that year, Archemix had filed - but had been unable to get to - IPO. The firm opted instead to merge with the publicly traded NitroMed. In January 2009, NitroMed entered into a merger agreement to be acquired by affiliates of Deerfield Management, a leading healthcare investment organization. Prior to entering into that merger agreement, NitroMed terminated its previously announced merger agreement with Archemix Corporation paying a $1.5 million fee to Archemix. Despite a wealth of working relationships with major players across the industry, the firm went into liquidation mode including selling its Hemophilia assets to Baxter
